On this page
SYN1
synapsin I
SYN1 encodes synapsin I, a protein essential for regulating neurotransmitter release at synapses, with variants linked to epilepsy and intellectual disability. The SYN1 gene provides instructions for making synapsin I, a protein that helps control the release of chemical messengers in the brain.
SYN1 is located on the short (p) arm of chromosome X, at band Xp11.3-p11.23. Arm ratio per GRCh38 - banding schematic.
Explore chromosome X in the library →Available at Jeen Health
Clinical tests that include this
Overview
The SYN1 gene encodes synapsin I, a neuronal protein that plays a central role in regulating neurotransmitter release at synapses. Synapsin I belongs to a family of phosphoproteins found in nerve terminals throughout the central nervous system, where it helps organise and maintain pools of synaptic vesicles - the tiny membrane-bound structures that store neurotransmitters before their release.
Because SYN1 is situated on the X chromosome, pathogenic variants follow an X-linked inheritance pattern. Males, who have only one X chromosome, are typically more severely affected when they inherit a disease-causing variant. Females, with two X chromosomes, may show milder symptoms or remain unaffected depending on patterns of X-chromosome inactivation. Variants in SYN1 have been associated with epilepsy syndromes and intellectual disability, reflecting the protein's essential function in coordinating neuronal signalling during brain development and throughout life.
What the gene does
Synapsin I functions as a key regulator of synaptic vesicle dynamics within nerve terminals. The protein associates with synaptic vesicles and tethers them to the cytoskeleton, maintaining a reserve pool of vesicles that can be mobilised when neurons need to release neurotransmitters rapidly. This tethering mechanism ensures that neurons have sufficient vesicles available to sustain ongoing signalling, particularly during periods of intense activity.
The activity of synapsin I is controlled through phosphorylation - the addition of phosphate groups by enzymes called kinases. When specific sites on the protein are phosphorylated in response to neuronal activity, synapsin I releases its hold on synaptic vesicles, allowing them to move towards the presynaptic membrane and fuse with it to release their neurotransmitter cargo. This phosphorylation-dependent regulation enables synapsin I to respond dynamically to changes in neuronal activity, effectively coupling the availability of synaptic vesicles to the demands of neurotransmission.
Beyond its role in vesicle trafficking, synapsin I appears to influence synapse formation and maturation during brain development. Research suggests the protein helps stabilise newly formed synaptic contacts and may contribute to activity-dependent changes in synaptic strength, processes that are fundamental to learning and memory. The protein is particularly abundant in inhibitory neurons that use GABA as their neurotransmitter, which may explain why SYN1 variants often manifest as epilepsy, a disorder characterised by imbalances between excitatory and inhibitory signalling.
Video: Genetics 101
Chromosome location
SYN1 is located on the short arm of the X chromosome at position Xp11.23, a region that spans approximately 4 megabases. The gene comprises 13 exons that encode a mature protein of 705 amino acids. Its position on the X chromosome determines the X-linked inheritance pattern observed in families carrying pathogenic variants.
The Xp11.23 region contains several other genes involved in neurological function, and structural variants affecting this chromosomal segment can sometimes lead to more complex clinical presentations. The relatively compact structure of SYN1, combined with its location in a gene-rich region, means that large deletions or duplications in this area may affect neighbouring genes as well.
Protein structure
The synapsin I protein comprises 705 amino acids organised into several distinct functional regions. The N-terminal portion includes an A region spanning amino acids 1-28, followed by a B linker region from amino acids 29-112. The central C region, extending from amino acids 113-420, contains the principal functional domains responsible for both actin-binding and synaptic-vesicle binding - these activities are essential for the protein's role in tethering vesicles to the cytoskeletal framework.
Large segments of the protein are classified as disordered, including amino acids 1-73 at the N-terminus and a substantial stretch from amino acids 418-689 near the C-terminus. These disordered regions are thought to provide structural flexibility that allows synapsin I to interact with multiple binding partners and respond to phosphorylation signals. The D region, spanning amino acids 421-655, is particularly rich in proline residues and functions as a linker, while the E region comprises the final amino acids 656-705 at the C-terminus. The presence of extensive disordered regions is common in proteins that undergo dynamic regulation through post-translational modifications, enabling rapid conformational changes in response to cellular signals.
Key variants
Pathogenic variants in SYN1 are relatively uncommon but have been identified in families with X-linked epilepsy and intellectual disability. The types of variants reported include missense changes that alter single amino acids, nonsense variants that introduce premature stop signals, and small deletions or insertions that cause frameshift variants, disrupting the reading frame. Because the protein contains multiple functional regions, the location of a variant within the gene can influence the specific features observed in affected individuals.
Males carrying a pathogenic SYN1 variant typically show more consistent and severe manifestations, while carrier females may experience variable presentations ranging from no symptoms to seizures and mild cognitive impairment. This variability in females reflects random X-chromosome inactivation, the process by which one X chromosome is silenced in each cell. The specific pattern of inactivation can substantially influence whether a female carrier develops clinical features.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1001del | p.Asn334fs | Pathogenic | ★★☆☆ | Epilepsy, X-linked 1, with variable learning disabilities and behavior disorders |
c.1258dup | p.Arg420fs | Pathogenic | ★★☆☆ | Epilepsy, X-linked 1, with variable learning disabilities and behavior disorders |
c.1264C>T | p.Arg422Ter | Pathogenic | ★★☆☆ | Epilepsy, X-linked 1, with variable learning disabilities and behavior disorders |
c.1439dup | p.Leu481fs | Pathogenic/Likely pathogenic | ★★☆☆ | Epilepsy, X-linked 1, with variable learning disabilities and behavior disorders |
c.1447C>T | p.Gln483Ter | Pathogenic | ★★☆☆ | Epilepsy, X-linked 1, with variable learning disabilities and behavior disorders |
c.2del | p.Met1fs | Pathogenic/Likely pathogenic | ★★☆☆ | Epilepsy, X-linked 1, with variable learning disabilities and behavior disorders |
c.361G>T | p.Glu121Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Epilepsy, X-linked 1, with variable learning disabilities and behavior disorders |
c.528-2A>T | - | Pathogenic/Likely pathogenic | ★★☆☆ | Epilepsy, X-linked 1, with variable learning disabilities and behavior disorders |
c.700C>T | p.Arg234Ter | Pathogenic | ★★☆☆ | Intellectual disability, X-linked 50 |
c.745C>T | p.Gln249Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Intellectual disability |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Variants in SYN1 are primarily associated with epilepsy syndromes and intellectual disability. Affected individuals often present in early childhood with seizures that may be difficult to control with standard anti-epileptic medications. The epilepsy can take various forms, including generalised tonic-clonic seizures, focal seizures, or absence seizures, and the severity ranges from occasional episodes to frequent seizures that significantly impact daily life.
Intellectual disability associated with SYN1 variants is typically mild to moderate, though severity varies between individuals. Some affected males show speech delays, learning difficulties, and behavioural challenges such as attention deficits or autistic features. The combination of epilepsy and developmental delays reflects the protein's dual importance in regulating synaptic transmission and supporting normal brain development.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic SYN1 variants typically follow x-linked inheritance.
X-linked recessive: sons of a carrier mother have a 50% chance of being affected. Daughters have a 50% chance of being carriers.
UK clinical status
SYN1 is recognised within the UK National Health Service Genomic Medicine Service as a gene relevant to neurogenetic conditions. It appears on the current PanelApp Early Onset or Syndromic Epilepsy panel with a green rating (indicating diagnostic-grade evidence), reflecting strong evidence for its role in epilepsy. The gene is also listed on the Intellectual Disability panel with green status, reflecting its association with developmental delay and cognitive impairment.
Additionally, SYN1 is included in the Developmental Disorders Genotype-to-Phenotype (DDG2P) database with green status, a resource that curates genes reliably linked to developmental conditions. These panel memberships mean that SYN1 is routinely analysed when clinicians order genetic testing for individuals presenting with early-onset epilepsy or unexplained intellectual disability, particularly when family history suggests X-linked inheritance.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
Research into lifestyle modifications for individuals with SYN1-related epilepsy is limited, and general epilepsy management principles typically apply. Maintaining regular sleep patterns may be beneficial, as sleep deprivation is a recognised trigger for seizures in many epilepsy syndromes. Some evidence suggests that consistent routines and stress-reduction strategies can help reduce seizure frequency in susceptible individuals, though these observations are drawn from broader epilepsy populations rather than SYN1-specific studies.
Dietary interventions such as the ketogenic diet have shown efficacy in certain forms of epilepsy and are sometimes considered for individuals whose seizures prove resistant to medication. However, any such dietary approach should only be undertaken under close supervision by a healthcare team experienced in its implementation. Avoiding known seizure triggers - such as flashing lights in individuals with photosensitivity, alcohol (especially in excess) and recreational drug use - is advisable for anyone with epilepsy, including those with SYN1 variants.
Supplement considerations
There is no evidence that specific nutritional supplements can prevent or ameliorate seizures in individuals with SYN1-related epilepsy. While some vitamins and minerals, such as vitamin B6 and magnesium, have been investigated in the context of epilepsy management more broadly, research has not established that supplementation influences outcomes for SYN1 variant carriers specifically.
Individuals considering any supplement should discuss this with their healthcare provider, as some products can interact with anti-epileptic medications or affect seizure control. It is particularly important not to discontinue prescribed medications in favour of supplements, as this could lead to breakthrough seizures or status epilepticus, a medical emergency. Any nutritional intervention should complement, not replace, established medical management.
Frequently asked questions
How is SYN1-related epilepsy inherited?
SYN1-related epilepsy follows an X-linked inheritance pattern. Males are typically more severely affected because they have only one X chromosome, while females may show variable features depending on X-chromosome inactivation patterns. An affected male will not pass the variant to his sons but will pass it to all his daughters, who become carriers.
Can females with a SYN1 variant develop symptoms?
Yes, some females carrying a pathogenic SYN1 variant develop seizures or mild intellectual disability, though symptoms are generally less severe than in affected males. The variability in female carriers is due to random X-chromosome inactivation, which determines what proportion of their cells use the chromosome carrying the variant.
What types of seizures occur with SYN1 variants?
Individuals with SYN1 variants can experience various seizure types, including generalised tonic-clonic seizures, focal seizures, and absence seizures. The specific seizure pattern and frequency vary between affected individuals, and some may have multiple seizure types.
Is genetic testing for SYN1 available on the NHS?
Yes, SYN1 is included on NHS genetic testing panels for early-onset or syndromic epilepsy and intellectual disability. Testing is typically arranged through specialist clinics when an individual's clinical presentation and family history suggest a possible genetic cause.
Can SYN1-related epilepsy be treated?
Epilepsy associated with SYN1 variants is managed with anti-epileptic medications, though seizure control can be challenging in some individuals. Treatment is individualised based on seizure type and response, and a neurology specialist should guide medication choices and adjustments.